Featured Research

from universities, journals, and other organizations

Multiple sclerosis drug prevents fatal heart condition in lab study

Date:
January 30, 2012
Source:
Manchester University
Summary:
A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found. Scientists found that Gilenya, a drug recently approved in the US for treating MS, was effective at reversing the symptoms of ventricular hypertrophy in mice.

Related Articles


Ventricular hypertrophy is a fatal cardiac disorder that can result in an abnormal heart rhythm (arrhythmia) and cardiac arrest. It is caused by sustained pressure on the heart due to stresses or diseases, such as hypertension (high blood pressure), valvular heart disease or myocardial infarction (heart attack), and is the leading cause of sudden cardiac death worldwide.

Researchers from The University of Manchester and the University of Illinois at Chicago have discovered that enhancing the activity of an enzyme molecule called Pak1 that is found naturally in our bodies using Gilenya produced remarkable results in mice with ventricular hypertrophy.

Study co-author Dr Xin Wang, a Lecturer in Molecular Cardiology in Manchester's Faculty of Life Sciences, said: "Cardiac hypertrophy is the pathological state to respond to sustained stresses on the heart resulting in increases in ventricular wall thickness and muscle mass of the heart. The condition is often associated with fatal complications, such as, heart failure and rhythm disorders, such as ventricular arrhythmias, leading to millions of deaths worldwide each year.

"Our research had previously identified the effect of Pak1 in preventing tissue damage caused by reduced blood flow to the heart, known as cardiac ischemic injury. This latest study used mice with a genetic modification of the Pak1 gene to show how the enzyme, when stimulated by Gilenya, prevented and even reversed the symptoms of ventricular hypertrophy."

The research, led in Manchester by Dr Ming Lei, Dr Xin Wang and Dr Elizabeth Cartwright, and in Chicago by Professor John Solaro and Dr Yunbo Ke, is published in the leading cardiovascular journal, Circulation.

Dr Lei, who is based in Manchester's Faculty of Medical and Human Sciences, added: "In recent years, escalating costs, risks, and uncertainty associated with drug development for treating cardiovascular diseases have posed daunting challenges to the pharmaceutical industry. Our discovery opens up fresh avenues for developing a new class of drug for treating several fatal heart conditions. The novel effect of this existing drug means that we have the potential to accelerate the availability of a new therapy for patients with these heart conditions."

The work is being funded in the UK by the British Heart Foundation and the Medical Research Council.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. W. Liu, M. Zi, R. Naumann, S. Ulm, J. Jin, D. M. Taglieri, S. Prehar, J. Gui, H. Tsui, R.-P. Xiao, L. Neyses, R. J. Solaro, Y. Ke, E. J. Cartwright, M. Lei, X. Wang. Pak1 as a Novel Therapeutic Target for Antihypertrophic Treatment in the Heart. Circulation, 2011; 124 (24): 2702 DOI: 10.1161/CIRCULATIONAHA.111.048785

Cite This Page:

Manchester University. "Multiple sclerosis drug prevents fatal heart condition in lab study." ScienceDaily. ScienceDaily, 30 January 2012. <www.sciencedaily.com/releases/2012/01/120130093658.htm>.
Manchester University. (2012, January 30). Multiple sclerosis drug prevents fatal heart condition in lab study. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2012/01/120130093658.htm
Manchester University. "Multiple sclerosis drug prevents fatal heart condition in lab study." ScienceDaily. www.sciencedaily.com/releases/2012/01/120130093658.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Breakfast Debate: To Eat Or Not To Eat?

Breakfast Debate: To Eat Or Not To Eat?

Newsy (Oct. 23, 2014) Conflicting studies published in the same week re-ignited the debate over whether we should be eating breakfast. Video provided by Newsy
Powered by NewsLook.com
Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Despite Rising Death Toll, Many Survive Ebola

Despite Rising Death Toll, Many Survive Ebola

AP (Oct. 23, 2014) The family of a Dallas nurse infected with Ebola in the US says doctors can no longer detect the virus in her. Despite the mounting death toll in West Africa, there are survivors there too. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins